Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigations

A Tyrosine Kinase Inhibitor–Based High-Affinity PET Radiopharmaceutical Targets Vascular Endothelial Growth Factor Receptor

Feng Li, Sheng Jiang, Youli Zu, Daniel Y. Lee and Zheng Li
Journal of Nuclear Medicine September 2014, 55 (9) 1525-1531; DOI: https://doi.org/10.2967/jnumed.114.138925
Feng Li
1Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheng Jiang
2Laboratory of Medicinal Chemistry, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Youli Zu
3Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Y. Lee
1Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheng Li
1Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 55 no. 9 1525-1531
DOI 
https://doi.org/10.2967/jnumed.114.138925
PubMed 
24970912

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication February 11, 2014
  • Accepted for publication May 6, 2014
  • Published online September 2, 2014.

Article Versions

  • previous version (June 26, 2014 - 05:20).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. Feng Li1,
  2. Sheng Jiang2,
  3. Youli Zu3,
  4. Daniel Y. Lee1 and
  5. Zheng Li1
  1. 1Department of Translational Imaging, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas
  2. 2Laboratory of Medicinal Chemistry, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China; and
  3. 3Department of Pathology and Genomic Medicine, Houston Methodist Research Institute, Weill Cornell Medical College, Houston, Texas
  1. For correspondence or reprints contact: Zheng Li, Houston Methodist Research Institute, 6670 Bertner St., Houston, TX 77030. E-mail: zli{at}houstonmethodist.org
View Full Text

Statistics from Altmetric.com

Cited By...

  • 20 Citations
  • 23 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Copper radiopharmaceuticals for theranostic applications
    Anife Ahmedova, Boyan Todorov, Nikola Burdzhiev, Christine Goze
    European Journal of Medicinal Chemistry 2018 157
  • Focused ultrasound for opening blood-brain barrier and drug delivery monitored with positron emission tomography
    Wejdan M. Arif, Philip H. Elsinga, Carmen Gasca-Salas, Michel Versluis, Raul Martínez-Fernández, Rudi A.J.O. Dierckx, Ronald J.H. Borra, Gert Luurtsema
    Journal of Controlled Release 2020 324
  • Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC–ESI–MS/MS
    Mohamed W. Attwa, Adnan A. Kadi, Hany W. Darwish, Sawsan M. Amer, Nasser S. Al-shakliah
    Chemistry Central Journal 2018 12 1
  • PET Imaging of VEGFR with a Novel 64Cu-Labeled Peptide
    Kuan Hu, Jingjie Shang, Lin Xie, Masayuki Hanyu, Yiding Zhang, Zhimin Yang, Hao Xu, Lu Wang, Ming-Rong Zhang
    ACS Omega 2020 5 15
  • Multivalent Probes in Molecular Imaging: Reality or Future?
    Verena I. Böhmer, Wiktor Szymanski, Ben L. Feringa, Philip H. Elsinga
    Trends in Molecular Medicine 2021 27 4
  • Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging
    Vadim Bernard-Gauthier, Justin Bailey, Sheldon Berke, Ralf Schirrmacher
    Molecules 2015 20 12
  • Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation
    Sawsan M. Amer, Adnan A. Kadi, Hany W. Darwish, Mohamed W. Attwa
    Chemistry Central Journal 2017 11 1
  • Metal‐Containing Pharmacophores in Molecularly Targeted Anticancer Therapies and Diagnostics
    Mu Yang, Ulrich Bierbach
    European Journal of Inorganic Chemistry 2017 2017 12
  • Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
    Julie Bolcaen, Shankari Nair, Cathryn Driver, Tebatso Boshomane, Thomas Ebenhan, Charlot Vandevoorde
    Pharmaceuticals 2021 14 7
  • Redox-responsive controlled DNA transfection and gene silencing based on polymer-conjugated magnetic nanoparticles
    Lei Zhang, Yecheng Li, Jimmy C. Yu, King Ming Chan
    RSC Advances 2016 6 76

Article usage

Article usage: June 2014 to April 2025

AbstractFullPdf
Jun 2014169031
Jul 2014217027
Aug 2014114012
Sep 20145091356
Oct 2014164719
Nov 201495210
Dec 2014521911
Jan 201579713
Feb 20153046
Mar 2015532728
Apr 201533810
May 201547813
Jun 2015242121
Jul 2015211018
Aug 2015381117
Sep 201539208
Oct 201515910
Nov 2015241812
Dec 201551139
Jan 201640186
Feb 2016321914
Mar 201611717
Apr 2016201419
May 201624624
Jun 2016231218
Jul 201616615
Aug 201618713
Sep 2016301310
Oct 20162186
Nov 2016191012
Dec 2016201210
Jan 201722176
Feb 201730211
Mar 201717112
Apr 201710105
May 20171762
Jun 20171379
Jul 201718145
Aug 2017192211
Sep 2017161014
Oct 2017221819
Nov 2017181314
Dec 201717175
Jan 2018252117
Feb 2018221514
Mar 20182385
Apr 201822166
May 2018301611
Jun 2018193410
Jul 201831225
Aug 201811177
Sep 2018201612
Oct 2018231912
Nov 201828195
Dec 201832163
Jan 201932286
Feb 201922383
Mar 201924386
Apr 2019264116
May 2019101012
Jun 201914710
Jul 201914215
Aug 2019152015
Sep 2019678
Oct 20191087
Nov 20191244
Dec 20191026
Jan 2020533
Feb 2020747
Mar 2020817
Apr 2020724
May 20201138
Jun 20201269
Jul 2020542
Aug 2020935
Sep 20201702
Oct 20207514
Nov 20201046
Dec 20205119
Jan 202151214
Feb 20212810
Mar 202141717
Apr 202143520
May 20212177
Jun 2021472
Jul 202131412
Aug 20211912
Sep 20211119
Oct 202121026
Nov 202133436
Dec 202133518
Jan 202242312
Feb 202271216
Mar 202222715
Apr 202201914
May 20223185
Jun 20221118
Jul 20220235
Aug 20220135
Sep 20221139
Oct 202261510
Nov 20223238
Dec 20222125
Jan 20238249
Feb 20232198
Mar 20233812
Apr 202321913
May 202311214
Jun 202321111
Jul 202332010
Aug 20231093
Sep 2023272
Oct 202381915
Nov 20236148
Dec 202313256
Jan 202442111
Feb 20246118
Mar 20241128
Apr 202413812
May 202410327
Jun 202492610
Jul 202451622
Aug 2024102927
Sep 202481717
Oct 20244175
Nov 202441412
Dec 202410139
Jan 202511111
Feb 202553512
Mar 20251269
Apr 202532323
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 55 (9)
Journal of Nuclear Medicine
Vol. 55, Issue 9
September 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A Tyrosine Kinase Inhibitor–Based High-Affinity PET Radiopharmaceutical Targets Vascular Endothelial Growth Factor Receptor
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
A Tyrosine Kinase Inhibitor–Based High-Affinity PET Radiopharmaceutical Targets Vascular Endothelial Growth Factor Receptor
Feng Li, Sheng Jiang, Youli Zu, Daniel Y. Lee, Zheng Li
Journal of Nuclear Medicine Sep 2014, 55 (9) 1525-1531; DOI: 10.2967/jnumed.114.138925

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Tyrosine Kinase Inhibitor–Based High-Affinity PET Radiopharmaceutical Targets Vascular Endothelial Growth Factor Receptor
Feng Li, Sheng Jiang, Youli Zu, Daniel Y. Lee, Zheng Li
Journal of Nuclear Medicine Sep 2014, 55 (9) 1525-1531; DOI: 10.2967/jnumed.114.138925
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • 11C-Methionine PET of Myocardial Inflammation in a Rat Model of Experimental Autoimmune Myocarditis
  • Counting Rate Characteristics and Image Distortion in Preclinical PET Imaging During Radiopharmaceutical Therapy
  • Design and Fabrication of Kidney Phantoms for Internal Radiation Dosimetry Using 3D Printing Technology
Show more Basic Science Investigations

Similar Articles

Keywords

  • vascular endothelial growth factor receptor (VEGFR)
  • tumor angiogenesis
  • 64Cu
  • theranostic
SNMMI

© 2025 SNMMI

Powered by HighWire